Brockmann B, Kirchhof I, Geschke E, Schmidt U M
Klinik und Poliklinik für Onkologie des Bereichs Medizin (Charité), Humboldt-Universität zu Berlin.
Arch Geschwulstforsch. 1989;59(5):341-6.
Remission rate of 30-50% can be obtained by different cytostatic combinations in second-line-therapy of the metastasized breast cancer. The combination of adriamycin and vincristine with cytostasan reveals a remission rate of 52% in 50 CMF-pretreated female patients. Considerable toxic side effects led to a dose reduction of cytostasan and adriamycin in 31 female patients without clinical efficiency loss. The long remission periods of the total responders (5+ -23 months) are remarkable. Both 3 female patients with bone +/- soft tissue metastasis and 3 female patients with visceral metastasis benefited from a clinical total remission. The remission rates indicated no significant differences between the group of patients with soft tissue +/- bone metastasis (56.3%) and that with a predominantly visceral metastasis (50.0%). The CyAV-combination with a low dose provides an effective therapeutical scheme with acceptable side effects for CMF-pretreated female patients with breast cancer.
在转移性乳腺癌的二线治疗中，不同的细胞抑制药物组合可使缓解率达到30%-50%。阿霉素、长春新碱与癌抑散联合应用，在50例接受过CMF方案预处理的女性患者中，缓解率达52%。31例女性患者出现明显的毒副作用，因此减少了癌抑散和阿霉素的剂量，但临床疗效并未降低。所有缓解者的缓解期较长（5±23个月），这一点很显著。3例有骨转移和/或软组织转移的女性患者以及3例有内脏转移的女性患者均实现了临床完全缓解。软组织和/或骨转移患者组（56.3%）与以内脏转移为主的患者组（50.0%）的缓解率无显著差异。低剂量的CyAV组合为接受过CMF方案预处理的乳腺癌女性患者提供了一种有效的治疗方案，且副作用可接受。
